Ganglan Fu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ganglan Fu has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Fengtao Ji
Affiliation Department of Anesthesiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
3 shared publicationsHaoquan Huang
Department of Anesthesiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
3 shared publicationsMeng Wang
Department of Cardiovascular Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
3 shared publications- Minghui Cao
Affiliation Department of Anesthesiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
3 shared publications Chuwen Hu
Department of Anesthesiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
2 shared publicationsFan Liu
Medical Research Center of Shenshan medical center, Sun Yat-sen Memorial Hospital, Shanwei, China
2 shared publications
Latest Publications
- Open Access
- 23 January 2026
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 22 (1) , e1012034
Shared latent genetic liability across fibromyalgia and psychiatric traits: Novel insights from genomic structural equation modeling
Background: Fibromyalgia, insomnia, depression, and anxiety share common clinical comorbidities, but their underlying genetic architecture and mechanism remain unclear. Methods: We conducted phenotype-specific Genome-wide association study (GWAS) meta-analyses for fibromyalgia, insomnia, depression, and anxiety, respectively. Genomic structural equation modeling was employed to identify a shared genetic factor (mvFibroPsych). Lead SNPs and associated genes were annotated using Functional Mapping and Annotation (FUMA), followed by gene-set and tissue enrichment analyses. The Latent Causal Variable (LCV) method was utilized to identify modifiable risk factors and phenotypes influenced by mvFibroPsych. Additionally, brain-wide and proteome-wide Mendelian randomization (MR) analyses were applied to explore brain regions and biomarkers associated with mvFibroPsych. Multi-layer molecular quantitative trait locus (QTL) analyses were conducted for mechanistic insights into mvFibroPsych. Results: Strong genetic correlations were observed among the four phenotypes (r g = 0.55–0.84), with excellent model fit for the common factor [comparative fit index (CFI) = 0.999, standardized root mean square residual (SRMR) = 0.015]. The mvFibroPsych GWAS identified 49 lead SNPs across 43 loci, including 32 novel loci. Gene prioritization revealed 342 protein-coding genes, and pathway analysis indicated enrichment in synaptic function pathway. LCV identified 133 phenotypes causally linked to mvFibroPsych. Brain-wide MR found fractional anisotropy in the splenium of the corpus callosum to be inversely associated with mvFibroPsych. Proteome-wide MR identified five proteins significantly associated with mvFibroPsych, while multi-layer brain QTL analysis prioritized CD40 as a potential target. Conclusions: This study provides strong evidence for a shared genetic factor underlying fibromyalgia, insomnia, depression, and anxiety, linked to synaptic function, brain structure integrity, and neuroinflammatory pathways.
- 23 January 2026
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 22 (1) , e1012034
Open AccessShared latent genetic liability across fibromyalgia and psychiatric traits: Novel insights from genomic structural equation modeling
Background: Fibromyalgia, insomnia, depression, and anxiety share common clinical comorbidities, but their underlying genetic architecture and mechanism remain unclear. Methods: We conducted phenotype-specific Genome-wide association study (GWAS) meta-analyses for fibromyalgia, insomnia, depression, and anxiety, respectively. Genomic structural equation modeling was employed to identify a shared genetic factor (mvFibroPsych). Lead SNPs and associated genes were annotated using Functional Mapping and Annotation (FUMA), followed by gene-set and tissue enrichment analyses. The Latent Causal Variable (LCV) method was utilized to identify modifiable risk factors and phenotypes influenced by mvFibroPsych. Additionally, brain-wide and proteome-wide Mendelian randomization (MR) analyses were applied to explore brain regions and biomarkers associated with mvFibroPsych. Multi-layer molecular quantitative trait locus (QTL) analyses were conducted for mechanistic insights into mvFibroPsych. Results: Strong genetic correlations were observed among the four phenotypes (r g = 0.55–0.84), with excellent model fit for the common factor [comparative fit index (CFI) = 0.999, standardized root mean square residual (SRMR) = 0.015]. The mvFibroPsych GWAS identified 49 lead SNPs across 43 loci, including 32 novel loci. Gene prioritization revealed 342 protein-coding genes, and pathway analysis indicated enrichment in synaptic function pathway. LCV identified 133 phenotypes causally linked to mvFibroPsych. Brain-wide MR found fractional anisotropy in the splenium of the corpus callosum to be inversely associated with mvFibroPsych. Proteome-wide MR identified five proteins significantly associated with mvFibroPsych, while multi-layer brain QTL analysis prioritized CD40 as a potential target. Conclusions: This study provides strong evidence for a shared genetic factor underlying fibromyalgia, insomnia, depression, and anxiety, linked to synaptic function, brain structure integrity, and neuroinflammatory pathways.
- Open Access
- 30 September 2025
- Published by Springer Nature in BMC Public Health
- Vol. 25 (1) , 1-16
Temporal trends in heart failure burden among young adults in China: a systematic analysis from 1990 to 2021
Studies from several countries have reported an increasing trend in heart failure (HF) among young adults, but comprehensive data on HF burden among young Chinese adults are lacking. Using data from the Global Burden of Disease Study 2021, we analyzed trends in prevalence and years lived with disability (YLDs) of HF among Chinese adults aged 20–49 years from 1990 to 2021. We examined age-standardized rates per 100,000 population, stratified by age groups, sex, severity levels, and underlying causes. Joinpoint regression, age-period-cohort analysis, decomposition analysis, frontier analysis and projection models were applied. From 1990 to 2021, HF prevalence cases increased from 448,261.89 to 897,595.61, while YLDs rose from 44,025.76 to 88,416.28. Age-standardized prevalence rates increased from 88.44 to 141.27 per 100,000 population, and YLD rates increased from 8.70 to 13.90, with average annual percentage changes (AAPC) of 1.53 (95% CI: 1.40–1.65) and 1.52 (95% CI: 1.42–1.61), respectively. Ischemic heart disease remained the leading cause (51.68 per 100,000), followed by hypertensive heart disease (29.25) and cardiomyopathy (15.83), while atrial fibrillation showed the highest relative increase (446%). Frontier analysis revealed a moderate gap (effective difference: 51.68) between China’s current and potentially achievable HF prevalence. Epidemiological changes (66.9%) drove the increased burden, with projections indicating continued rises through 2030. The burden of HF among young Chinese adults has increased substantially over the past three decades, with traditional cardiovascular causes remaining predominant. These findings highlight the urgent need for enhanced prevention strategies targeting young adults in China.
- 30 September 2025
- Published by Springer Nature in BMC Public Health
- Vol. 25 (1) , 1-16
Open AccessTemporal trends in heart failure burden among young adults in China: a systematic analysis from 1990 to 2021
Studies from several countries have reported an increasing trend in heart failure (HF) among young adults, but comprehensive data on HF burden among young Chinese adults are lacking. Using data from the Global Burden of Disease Study 2021, we analyzed trends in prevalence and years lived with disability (YLDs) of HF among Chinese adults aged 20–49 years from 1990 to 2021. We examined age-standardized rates per 100,000 population, stratified by age groups, sex, severity levels, and underlying causes. Joinpoint regression, age-period-cohort analysis, decomposition analysis, frontier analysis and projection models were applied. From 1990 to 2021, HF prevalence cases increased from 448,261.89 to 897,595.61, while YLDs rose from 44,025.76 to 88,416.28. Age-standardized prevalence rates increased from 88.44 to 141.27 per 100,000 population, and YLD rates increased from 8.70 to 13.90, with average annual percentage changes (AAPC) of 1.53 (95% CI: 1.40–1.65) and 1.52 (95% CI: 1.42–1.61), respectively. Ischemic heart disease remained the leading cause (51.68 per 100,000), followed by hypertensive heart disease (29.25) and cardiomyopathy (15.83), while atrial fibrillation showed the highest relative increase (446%). Frontier analysis revealed a moderate gap (effective difference: 51.68) between China’s current and potentially achievable HF prevalence. Epidemiological changes (66.9%) drove the increased burden, with projections indicating continued rises through 2030. The burden of HF among young Chinese adults has increased substantially over the past three decades, with traditional cardiovascular causes remaining predominant. These findings highlight the urgent need for enhanced prevention strategies targeting young adults in China.
- Open Access
- 18 June 2025
- Published by Taylor & Francis in Annals of Medicine
- Vol. 57 (1) , 2517820
Efficacy and safety of ciprofol for sedation/anesthesia in patients undergoing hysteroscopy: a prospective, randomized, non-inferiority trial
Propofol is the preferred sedative for painless hysteroscopy and other procedures due to its fast onset and short duration. However, its limitations, including injection pain, respiratory depression, blood pressure decline, and bradycardia, cannot be disregarded. Ciprofol, a new short-acting gamma-aminobutyric acid receptor agonist, has shown effectiveness and safety in painless gastrointestinal endoscopy. This study aims to demonstrate that ciprofol is not inferior to propofol in terms of sedation efficacy for painless hysteroscopy. A randomized study was conducted with 124 women to evaluate the anesthetic effect of ciprofol during outpatient painless hysteroscopy. The primary outcome assessed was the success rate of hysteroscopy, while secondary indicators included induction and recovery time, injection pain, tidal volume and respiratory rate. Safety indicators comprised hypotension, hypoxemia, and sinus bradycardia. A total of 124 patients were enrolled in the study, with 62 in each group. The success rate of hysteroscopy was 100% in both groups. Patients in the ciprofol group had higher diastolic pressure, pulse oxygen saturation levels and minute breathing during surgery than patients in the propofol group, but their induction time and recovery time were longer. The proportion of patients in the propofol group who reported pain during intravenous anesthesia was 41.935%, which was significantly higher than that of patients in the ciprofol group (1.613%). During painless hysteroscopy, ciprofol demonstrates non-inferiority to propofol in terms of anesthetic efficacy. Despite slightly longer induction and recovery times, ciprofol results in lower instances of injection pain and less impact on respiration and circulation compared to propofol. Clinical trial Registration Identifier: NCT06172140.
- 18 June 2025
- Published by Taylor & Francis in Annals of Medicine
- Vol. 57 (1) , 2517820
Open AccessEfficacy and safety of ciprofol for sedation/anesthesia in patients undergoing hysteroscopy: a prospective, randomized, non-inferiority trial
Propofol is the preferred sedative for painless hysteroscopy and other procedures due to its fast onset and short duration. However, its limitations, including injection pain, respiratory depression, blood pressure decline, and bradycardia, cannot be disregarded. Ciprofol, a new short-acting gamma-aminobutyric acid receptor agonist, has shown effectiveness and safety in painless gastrointestinal endoscopy. This study aims to demonstrate that ciprofol is not inferior to propofol in terms of sedation efficacy for painless hysteroscopy. A randomized study was conducted with 124 women to evaluate the anesthetic effect of ciprofol during outpatient painless hysteroscopy. The primary outcome assessed was the success rate of hysteroscopy, while secondary indicators included induction and recovery time, injection pain, tidal volume and respiratory rate. Safety indicators comprised hypotension, hypoxemia, and sinus bradycardia. A total of 124 patients were enrolled in the study, with 62 in each group. The success rate of hysteroscopy was 100% in both groups. Patients in the ciprofol group had higher diastolic pressure, pulse oxygen saturation levels and minute breathing during surgery than patients in the propofol group, but their induction time and recovery time were longer. The proportion of patients in the propofol group who reported pain during intravenous anesthesia was 41.935%, which was significantly higher than that of patients in the ciprofol group (1.613%). During painless hysteroscopy, ciprofol demonstrates non-inferiority to propofol in terms of anesthetic efficacy. Despite slightly longer induction and recovery times, ciprofol results in lower instances of injection pain and less impact on respiration and circulation compared to propofol. Clinical trial Registration Identifier: NCT06172140.
- 21 June 2024
- Published by Elsevier in The Journal of Pain
- Vol. 25 (10) , 104610
Identifying Novel Proteins for Chronic Pain: Integration of Human Brain Proteomes and Genome-wide Association Data
- 21 June 2024
- Published by Elsevier in The Journal of Pain
- Vol. 25 (10) , 104610
Identifying Novel Proteins for Chronic Pain: Integration of Human Brain Proteomes and Genome-wide Association Data
- 15 June 2024
- Published by Elsevier in Journal of Clinical Anesthesia
- Vol. 97, 111509
A pharmacovigilance study of FDA adverse events for sugammadex
- 15 June 2024
- Published by Elsevier in Journal of Clinical Anesthesia
- Vol. 97, 111509
A pharmacovigilance study of FDA adverse events for sugammadex
- 5 March 2022
- Published by Elsevier in Journal of Stomatology Oral and Maxillofacial Surgery
- Vol. 123 (6) , e899-e905
Infusion management associated with prolonged length of stay following free flap reconstruction of head and neck defects: A propensity score matching study
- 5 March 2022
- Published by Elsevier in Journal of Stomatology Oral and Maxillofacial Surgery
- Vol. 123 (6) , e899-e905
Infusion management associated with prolonged length of stay following free flap reconstruction of head and neck defects: A propensity score matching study